LAVA Therapeutics Enters Clinical Collaboration with Merck to Evaluate LAVA-1207 in Combination with KEYTRUDA® for mCRPC

On January 25, Dutch biotechnology developer LAVA Therapeutics announced that it had signed a clinical trial collaboration and supply agreement with MSD to evaluate the effects of MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in combination with LAVA-1207 for the treatment of refractory metastatic castration-resistant prostate cancer (mCRPC) patients.